Selective tile review brings pathologist-like efficiency to whole-slide analysis

Artificial intelligence in digital pathology has reached a familiar bottleneck: accuracy keeps improving, but the compute burden often grows with it. Whole-slide images contain millions of pixels, and many current pipelines still chew through thousands of tiles per slide, most of them uninformative or redundant. EAGLE, short for Efficient Approach for Guided Local Examination, was built to answer that problem with a more disciplined reading strategy. Rather than treating every region of tissue as equally valuable, the framework first identifies informative areas and then performs deeper feature extraction where the biology is most likely to matter.

The result is a model designed to mirror how an experienced pathologist works at the microscope. A human reviewer does not examine every square micron with equal intensity; instead, the eye moves toward tumor-rich zones, architectural distortion, inflammatory interfaces, and other visually meaningful regions. EAGLE uses that same logic in computational form, pairing task-agnostic tile selection with detailed downstream analysis. The practical advantage is immediate: the framework processed one slide in 2.27 seconds and reduced computational time by more than 99% compared with existing models.

Performance across 43 tasks and nine cancer types

EAGLE was benchmarked against leading slide-level and tile-level foundation models across 43 tasks spanning nine cancer types. Those tasks covered morphology, biomarker prediction, treatment response, and prognosis, a broad mix that reflects the current ambitions of computational pathology in oncology. The framework outperformed patch aggregation methods by as much as 23% and delivered the highest overall classification performance in the comparison set.

The breadth of testing matters because pathology models often look impressive in one narrow setting and then weaken when moved to a different tumor type, endpoint, or imaging task. Here, the evaluation spanned multiple cancers and multiple clinical questions, giving the framework a more demanding proving ground. Strong performance across morphology and outcome-linked tasks suggests that the selected tiles contained enough biologic signal to support several downstream use cases, rather than just one isolated classification challenge.

Computational speed alone would be a narrow story if the model sacrificed interpretability. It did not. EAGLE was built to make review auditable by enabling users to inspect the exact tiles that informed each prediction. In clinical workflows, that transparency is not cosmetic; it shapes trust, error detection, and eventual regulatory adoption.

Why fewer tiles can produce better pathology intelligence

The design principle behind EAGLE is biologically intuitive. Many slides contain large areas of stroma, normal tissue, necrosis, blood, artifact, or bland regions that add noise without advancing the diagnostic question. A model that processes all of those regions with equal weight risks wasting computation and diluting the signal from the tissue that actually carries the answer. By concentrating analysis on informative regions, the framework reduces the influence of irrelevant background and may improve robustness when slides include artifacts or uneven tissue distribution.

A single slide can now move through analysis in seconds rather than minutes or longer.

This kind of acceleration has direct implications for pathology operations. Faster inference can support higher-throughput workflows, lower hardware dependence, and easier deployment in settings where access to high-performance computing is limited. It can also make large-scale retrospective studies more feasible, particularly when investigators need to score thousands of archival slides for biomarker discovery or prognostic modeling. In that sense, the framework is not just a faster classifier; it is an operational bridge between research-grade digital pathology and more practical, scalable implementation.

The negative-control and attention analyses strengthen that case. Systematic negative controls help show whether the model is responding to meaningful tissue patterns rather than spurious shortcuts, while attention concentration analyses probe whether signal is being focused where it should be. In pathology AI, those checks are essential because high accuracy can still emerge from brittle or misleading cues. A model that can surface the exact tiles it used, and do so while minimizing artifacts, is easier to inspect, reproduce, and challenge when its output conflicts with clinical judgment.

Auditable outputs, slide search, and multi-omics integration

EAGLE’s utility extends beyond classification performance. Its unified embedding supports rapid slide search, which opens the door to image retrieval systems that can find similar histologic patterns across large repositories. That capability could be useful for case triage, cohort assembly, and visual pattern exploration in translational research. The same embedding architecture also supports integration into multi-omics pipelines and emerging clinical foundation models, where image data must be aligned with molecular and clinical signals.

This is where the framework becomes more than a speed optimization. A compact and unified representation can serve as a shared language between histology and other data modalities, allowing investigators to compare tissue appearance with genomic, transcriptomic, or clinical features at scale. In oncology, where pathology often sits at the intersection of diagnosis and molecular stratification, that interoperability may matter as much as raw classification accuracy.

The study also points toward a more auditable future for computational pathology. Rather than handing clinicians a black-box score derived from thousands of indistinguishable patches, EAGLE can expose the regions that drove its call. That kind of traceability may be especially valuable in treatment-response prediction and prognosis, where model outputs are more likely to influence clinical discussion and research interpretation.

What the benchmark suggests for pathology practice

The key advance here is not simply that the framework performs well. It is that it combines high accuracy, strong computational efficiency, and a transparent review path in a single architecture. Those three properties often pull in different directions. Models that are highly interpretable can be slower or less powerful, while highly optimized systems can become opaque. EAGLE avoids that tradeoff by selecting informative tissue first and then preserving the evidence trail behind each prediction.

For digital pathology teams, that architecture could reduce the friction between experimentation and implementation. For clinical researchers, it may lower the cost of running large cohorts through AI analysis. For pathologists, it offers a model that behaves less like a brute-force image scanner and more like a constrained observer focused on biologically meaningful tissue.

The remaining question is not whether the framework can process slides quickly; it clearly can. The more consequential issue is how it will perform when moved into prospective workflows, external datasets, and settings where stain variation, fixation differences, and rare histologic patterns can expose model weakness. Those are the environments that will determine whether this selective approach remains robust outside benchmark conditions.


Reporting by Dr. Revathy Mohan V.R., MBBS for Medicine World Foundation, with additional data provided by Journal of the National Cancer Institute (JNCI).